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Abstract
Background: In addition to occipital hypoperfusion, preserved metabolism of the posterior cingulate gyri (PCG)
relative to the precunei is known as the cingulate island sign (CIS) in the patients with dementia with Lewy bodies
(DLB). CIS has been detected using [18F]fluorodeoxyglucose positron emission tomography but not using brain
perfusion single-photon emission computed tomography (SPECT). The purpose of this study was to optimize brain
perfusion SPECT to enable differentiation of DLB from Alzheimer’s disease (AD) using CIS and occipital
hypoperfusion.
Eighteen patients with probable DLB and 17 age-matched Pittsburgh compound B-positive patients with AD
underwent technetium-99m ethyl cysteinate dimer SPECT. SPECT Z-score maps were generated using the easy Z-
score imaging system (eZIS) analysis software (Matsuda H, Mizumura S, Nagao T, Ota T, Iizuka T, Nemoto K,
Takemura N, Arai H, Homma A, AJNR Am J Neuroradiol 28(4):731–6, 2007), which included volumes of interest
(VOIs) in which a group comparison between patients with AD and cognitively normal subjects revealed significant
relative hypoperfusion. We used the Montreal Neurological Institute (MNI) space anatomical border to divide the
bilateral PCG to precunei VOIs into two parts, the PCG and precunei. Z-scores in the PCG, precunei, and occipital
areas and ratios were analysed and compared with receiver operating characteristic (ROC) curve analyses.
Results: The largest area under the curve (AUC) value for use in differentiating DLB from AD with the ratio of PCG
to medial occipital was 0.87; the accuracy, sensitivity, and specificity were 85.7, 88.9, and 82.4 %, respectively.
The AUC with the ratio of PCG to the precuneus was smaller, and it was 0.85, though no significant difference was
observed between these two AUCs.
Conclusions: The Z-score ratio of the PCG within the early-AD-specific VOI to medial-occipital area is clinically
useful in discriminating demented patients with DLB from those with AD.
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Background
Dementia with Lewy bodies (DLB) is one of the most
frequent causes of dementia in elderly people, with
Alzheimer’s disease (AD) being the most prevalent
cause. It is clinically important to distinguish DLB
from AD because specific side effects of antipsychotic
drugs are limited to DLB. In discriminating DLB from
AD clinically, dopamine transporter (DAT) imaging [1]
and [123I]metaiodobenzylguanidine (MIBG) myocardial
scintigraphy [2] are useful because they detect early
disturbances of the nigrostriatum or peripheral sympa-
thetic nervous system in patients with DLB. Using a
combination of these two techniques, Shimizu et al. [3]
reported over 90 % sensitivity and specificity in dis-
criminating DLB from AD. However, brain perfusion
single-photon emission computed tomography (SPECT) is
more widely and commonly used for clinical screening
and examination of patients with dementia. Compared
with morphometric imaging, SPECT is a more sensitive
modality for functional imaging used to detect the early
stages of neurodegenerative disease before shrinkage [4].
SPECT also reveals useful information for differentiating
AD as well as other dementias, including vascular demen-
tia or frontotemporal lobe degeneration [5].
In patients with AD, proportional hypometabolism
and hypoperfusion are commonly observed in temporo-
parietal regions in general and in the posterior cingulate
gyri (PCG) in particular. Perfusion decreases observed in
patients with DLB overlap with those observed in pa-
tients with AD; however, more occipital hypometabolism
and hypoperfusion are reportedly observed in patients
with DLB [6, 7]. Conversely, Kemp et al. [8] reported
that only 28 % of hexamethylpropyleneamine oxime
(HMPAO) SPECT scans of patients with DLB revealed
occipital hypoperfusion.
In 1997, Imamura et al. [9] reported the relative
preservation of cingulate glucose metabolism in pa-
tients with DLB compared with those having AD. In
this study, brain perfusion SPECT analysis was opti-
mized for differentiation of AD from DLB. Lim et al.
[10] found that preservation of glucose metabolism in
the mid- or posterior cingulate, known as the cingu-
late island sign (CIS), is highly specific for diagnosing
DLB. They also reported that the sensitivities ranged
from 62 to 86 % for the CIS and from 43 to 50 % for
the medial occipital lobe. Graff-Radford et al. [11] re-
cently reported the results from an investigation using
[18F]fluorodeoxyglucose positron emission tomog-
raphy ([18F]FDG-PET) imaging and the pathologic as-
sociation of CIS with autopsy and carbon 11-labelled
Pittsburgh compound B ([11C]PiB) PET imaging in
patients with DLB. They concluded that the CIS was
indicative of the lower Braak neurofibrillary tangle
(NFT) stage in patients with DLB.
In contrast, O’Brien et al. [12] stated that the accuracy
of differentiating AD from DLB was disappointingly poor
and not yet at the level of being clinically useful. They also
claimed that brain perfusion SPECT imaging did not
reveal the CIS in patients with DLB. Therefore, in this
study, the entire precunei and PCG anatomical area was
not included and the CIS within the early-AD-specific vol-
umes of interest (VOIs) [13] was analysed. We aimed to
determine the usefulness of a Z-score map of technetium-
99m ethyl cysteinate dimer ([99mTc]ECD) brain perfusion
SPECT images for discriminating patients with DLB from
those with AD. Brain perfusion SPECT is not only more




This was a retrospective study that used data obtained at
a single medical centre.
All the subjects with AD were included in previously
reported paper from our institute [14]. This previous
study was approved by the National Center of Neurology
and Psychiatry Ethics Committee for Clinical Research,
and informed consent was obtained from all the sub-
jects. For our study, public notification was applied
according to the requirement of the ethical committee.
Then, the ethical committee approved our retrospective
study using preliminary obtained images.
At first, 20 of the PiB-positive patients who fulfil the
criteria of probable AD with a high level of evidence of
the AD pathophysiological process, with both atrophy
of the medial temporal lobe and decrease of the brain
perfusion by over two standard deviations based on the
Z-scores, were observed as described in this paper [14].
The [11C]PiB amyloid PET results were confirmed by
two board-certified nuclear medicine physicians. After
reinvestigation of clinical data and MRI, three patients
were excluded: one who was first diagnosed as DLB,
another had infarction in the brain stem on the T2-
weighted image, and the other had complication of
brain amyloid angiopathy. The average lag time be-
tween PET and SPECT acquisition was 1.40 ± 2.33
(mean ± SD) months.
For DLB, from chart screening, among all accessible pa-
tients who underwent brain perfusion SPECT, those fulfil
the probable DLB on the basis of the criteria proposed in
the third consortium on DLB international workshop [15]
were selected. Finally, 18 patients with probable DLB
(M/F = 10:8; age, 73.9 ± 6.8 years) and 17 patients with
AD (M/F = 6:11; age, 73.6 ± 8.9 years) were studied.
Brain perfusion SPECT
In advance, all patients received an intravenous line and
an intravenous injection of 740 MBq [99mTc]ECD (Fujifilm
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RI Pharma, Tokyo, Japan) was administered while lying
down with eyes closed in dark, quiet surroundings. The
global CBF was noninvasively measured using graphic
analysis as described previously [16–18], without blood
sampling. The passage of tracer from the aortic arch to
the brain was monitored for 100 s at 1-s intervals. Regions
of interest (ROIs) were hand-drawn over the aortic arch
(ROIaorta) and both brain hemispheres (ROIbrain). A hemi-
spheric brain perfusion index (BPI) [16] was determined
before the start of the initial back diffusion of the tracer
from the brain to the blood as follows:
BPI ¼ 100 ku 10 ROIaortasize
ROIbrainsize
; ð1Þ
where ku is the unidirectional influx rate for the tracer
from the blood to the brain, determined by the slope of
the line in graphic analysis within the first 30 s after in-
jection. Then, BPI (x) was converted to global CBF
values (y) obtained by 133Xe inhalation SPECT studies
(y = 2.60x + 19.8) [16].
Ten minutes later, SPECT imaging was performed on
a two-head gamma camera and six-slice CT system
(Symbia T6; Siemens, Erlangen, Germany) equipped
with low-energy, high-resolution, and parallel-hole col-
limators. Ninety views were obtained continuously
throughout 360° of rotation (4°/step, 128 × 128 matrix,
zoom 1.45). The voxel size was 3.3 × 3.3 × 3.3 mm. To
reconstruct the SPECT image, a combination of Fourier
rebinning followed by ordered subset expectation
maximization (iteration number 8 and subset 10) and a
7-mm full width at half maximum Gaussian filter was
used. Attenuation correction was performed using the
CT data and Chang’s method [19]. CT attenuation-
corrected images were used for measuring global CBF,
and Chang’s attenuation-corrected images were used
for Z-score analysis because the database included in the
software was reconstructed using Chang’s attenuation-
correction methods. To calculate CBF and to correct for
incomplete retention of [99mTc]ECD in the brain, the
following linearization algorithm [20] of a curve-linear









where Fi and Fr represent CBF values for a region I and
a reference region, respectively, and Ci and Cr are the
SPECT counts for the region i and the reference region,
respectively. The cerebral hemisphere was used as the
reference region, and global CBF obtained from the
graphic analysis was substituted for Fr. The linearization
factor a was set to 2.59, which was a proposed value by
Friberg et al. [20].
Image preprocessing
Z-score maps of the obtained SPECT images were
converted using the easy Z-score imaging system
(eZIS) analysis software (Fujifilm RI Pharma Co., Ltd.,
Tokyo, Japan). It included spatial normalization pa-
rameters in statistical parametric mapping (SPM)2
(http://www.fil.ion.ucl.ac.uk/spm/) and a [99mTc]ECD
brain template in the same space as the Montreal
Neurological Institute (MNI) standard brain template.
Normal databases are included in this software, and
inter-institutional differences can be corrected. That
is, correction can be made for data obtained in the in-
stitute where the database was built, using previously
scanned Hoffman 3-D Brain Phantom™ data.
After the inter-institutional correction, specially normal-
ized [99mTc]ECD SPECT images from each patient were
compared with normal images from the age-matched
database: ECD60-69y DB and ECD70y DB, using voxel-
by-voxel Z-score analysis after pixel normalization to the
global mean values [Z-score = ([control mean] − [indi-
vidual value])/(control SD)] as previously reported by
Minoshima et al. [21]. The VOIs in areas of significant
perfusion reduction were included in this software;
these areas were identified in patients with AD follow-
ing a group comparison with cognitively healthy indi-
viduals [22]. Among these preset VOIs, we chose VOIs
that were set within the bilateral posterior cingulate to
the precunei area; we then used the border between
the Cingulum_VOIs and the Precuneus_VOIs in the
Automated Anatomical Labeling (AAL) atlas to split
the VOIs into two parts, the bilateral PCG_AD_VOIs
and the Precuneus_AD_VOIs (Fig. 1). We also assem-
bled VOIs in the medial and lateral occipital areas in
this atlas and constructed the Medial_Occipital_VOI
and the Lateral_Occipital_VOI. Additionally, we con-
structed the Whole_Occipital_VOI as the sum of these
two VOIs. Then, we summated the positive Z-scores
within each VOI.
For the CIS, we first divided each value: the sum of all
the positive Z-scores in the PCG_AD_VOI by that in the
Precuneus_AD_VOI and named it as CISpreC. Second,
in order to compare the value of cingulate preservation
to the value of occipital hypoperfusion, we divided the
PCG_AD_VOI by the Medial_Occipital_VOI, the Latera-
l_Occipital_VOI, or the Whole_Occipital_VOI. We
named their three values as CISmedO, CISlatO, and
CISwO; CISmedO = PCG_AD_VOI/Medial_Occipital_-
VOI, CISlatO = PCG_AD_VOI/Lateral_Occipital_VOI,
and CISwO = PCG_AD_VOI/Whole_Occipital_VOI.
The area under the receiver operating characteristic
(ROC) curve (AUC) was obtained by thresholding each
Imabayashi et al. EJNMMI Research  (2016) 6:67 Page 3 of 8
of these values for all VOIs, CISpreC, CISmedO,
CISlatO, and CISwO. Finally, the AUCs were statistically
compared [23] (Table 2).
We also added group comparison between AD and
DLB subjects using SPM2. We added the results as
Additional file 1 (Fig. 2). VOIs used for analyses were in-
tegrated in the images.
Results
The patient characteristics are summarized in Table 1.
No significant difference was observed for age and gen-
der. The disease duration was longer in patients with
DLB. The mean cerebral blood flow of the whole brain
was significantly lower in patients with DLB. All the
heart-to-mediastrum ratios in [123I]MIBG scanned 3 h
after injection in patients with DLB were below 2.0.
The AUCs and the statistical results are shown in
Table 2. The greatest AUC value was 0.873 when the ra-
tio was the sum of all the positive Z-scores within the
PCG_AD_VOIs to those in the Medial_Occipital_VOIs;
CISmedO were used as thresholds. The accuracy, sensi-
tivity, and specificity were 85.7, 88.9, and 82.4 %, re-
spectively, for differentiating patients with DLB from
those with AD. According to the AUC comparison, the
AUC calculated using CISpreC was smaller but not sig-
nificantly different from the AUC thresholded with CIS-
medO; the accuracy, sensitivity, and specificity were
80.0, 66.7, and 94.1 %, respectively.
The AUCs thresholded with occipital VOIs were sig-
nificantly smaller than the AUCs thresholded with
CISpreC. Box plots of the CISpreC and the three oc-
cipital VOIs are shown in Fig. 3.
Discussion
Lim et al. [10] reported that the accuracy of differenti-
ating AD from DLB using the ratio of the posterior
cingulate to the surrounding cortex was 78 % with vis-
ual inspection of [18F]FDG-PET images. They found
reduced glucose metabolism in the lateral occipital
area but preserved glucose metabolism in the mid- or
Fig. 1 Volumes of interest (VOIs). The areas are the parts of the
early Alzheimer’s disease (AD)-specific VOIs in the easy Z-score
imaging system (eZIS) located in the posterior cingulate to the
precunei area. Blue area: Precuneus_AD_VOIs which are the areas
of overlap of the precuneus VOIs in the Automated Anatomical
Labeling (AAL) atlas and the early-AD-specific VOIs. Red area:
Posterior_Cingulate_AD_VOIs which are the areas of overlap of
the cingulum VOIs in the AAL atlas and the early-AD-specific VOIs
Fig. 2 Significance maps (uncorrected p < 0.01, with extent threshold k=400 voxels) superimposed on a T1-weighted brain MRI template image in
the Montreal Neurological Institute (MNI) space. The colour bar represents the t value. a Significance maps of proportionally decreased brain
perfusion in patients with DLB comparing with patients with AD. b Significance maps of proportionally increased brain perfusion in patients with
DLB comparing with patients with AD. AD Alzheimer’s disease, DLB dementia with Lewy bodies, MRI magnetic resonance imaging
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posterior cingulate; this phenomenon, known as CIS,
is specific to DLB.
A previous study [24] showed that the most significant
differences in the region of interest (ROI) analysis of
brain perfusion images between the AD and DLB groups
were in the occipital area and the precuneus. Conversely,
another study [8] reported that a diagnosis of DLB could
not be ruled out in using occipital hypoperfusion. There-
fore, in our study, we compared the Z-score of the
occipital area and the CIS to differentiate patients with
DLB from those with AD. We found that the Z-score
ratio of the posterior cingulate to the precuneus was
superior to the occipital Z-score for the purpose of dis-
criminating DLB from AD.
The demographic data showed that patients with DLB
had a lower cerebral blood flow value compared with
that found in patients with AD. This result is consistent
with that from a previous report [25]. Fong et al. [26]
reported that this hypoperfusion may be a potential
indicator of cholinergic dysfunction. They observed im-
provements in both hypoperfusion and cognitive impair-
ments with arterial spin-labelled perfusion magnetic
resonance imaging (MRI) after loading a single dose of
cholinesterase inhibitor. In the early stage, quantitative
cerebral blood flow might be used as a referential par-
ameter to differentiate AD from DLB; however, we
cannot eliminate other reasons for the induction of hy-
poperfusion. Our results suggested that the CIS could
be more useful as a specific indicator to differentiate
AD from DLB using brain perfusion SPECT.
Recently, Graff-Radford et al. [11] reported results of a
comparison of the CIS in [18F]FDG-PET and [11C]PiB-
PET scans. They also investigated autopsy results using
the CIS. They concluded that the CIS was indicative of a
lower Braak NFT stage in patients with DLB; however, it
was not associated with fibrillary β-amyloid deposition.
In our study, we compared the CIS detected using brain
perfusion SPECT in patients with DLB and AD. We can-
not compare these two studies directly because they did
not describe the discrimination accuracy. The greater
overlap observed in the box plots from our SPECT study
suggested that the CIS observed using [18F]FDG-PET
might more accurately discriminate patients with DLB
from those with AD. Brain perfusion and metabolism
are physiologically coupled [27]. The limitations of
SPECT include lower image resolution and a large par-
tial volume effect. These limitations in conjunction with
a patient’s pathological status result in decreased accur-
acy when attempting to differentiate between DLB and
AD using brain perfusion SPECT. However, SPECT is
widely accessible and more economical.
O’Brien et al. [12] found that the accuracy of differen-
tiating AD from DLB was disappointingly poor and not
at a level where it is likely to be clinically useful. They
showed that, even with FDG, the differentiation accuracy
was 72.4 %. Further, the CIS was not observed in the
SPECT images in their study. In our study, the high ac-
curacy (80.0 %) was obtained when a CISpreC value of
0.54 was used for thresholding. We used the software-
provided VOIs obtained from a group comparison be-
tween patients with AD and cognitively normal subjects.
We divided these VOIs into the precuneus area and the
posterior cingulate area along the anatomical border. Be-
cause AD and DLB are known to have pathological over-
lap and it is difficult to distinguish these two diseases
using [18F]FDG-PET or brain perfusion SPECT [12], it is
logical to use these early-AD-specific VOIs to discrimin-
ate AD from DLB.
Though all patients with AD underwent [11C]PiB
amyloid PET, none of the patients with DLB did; this
was due to the retrospective nature of the investigation,
which was based on clinical diagnoses. The percentage
of PiB-positive scans in patients with DLB ranged
Table 1 Demographic data
AD DLB
Age at the time of SPECT 74.4 ± 8.5 73.9 ± 6.8
Male/female 5/12 10/8
Disease duration at the time
of SPECT (years)
2.0 ± 1.6 4.0 ± 2.3**
MMSE 21.5 ± 3.3 19.1 ± 6.7
Cerebral blood flow
(mean; mL/100 g/min)
39.79 ± 3.22 36.86 ± 4.16*
Heart-to-mediastrum ratio in
[123I]MIBG (3 h after injection)
NA 1.33 ± 0.14
(range 1.09–1.62)
AD Alzheimer’s disease, DLB dementia with Lewy bodies, SPECT single-photon
emission computed tomography, MMSE Mini-Mental State Examination,
[123I]MIBG [123I]metaiodobenzylguanidine, NA not applicable
*p = 0.0200; **p = 0.0027
Table 2 Area under the receiver operating characteristic (ROC)
curve (AUC)
VOIs AUC ± SE 95 % CI pa
CISpreC 0.850 ± 0.068 0.688 to 0.947
CISmedO 0.873 ± 0.064 0.716 to 0.961 0.589
CISlatO 0.771 ± 0.081 0.598 to 0.896 0.271
CISwO 0.820 ± 0.074 0.654 to 0.929 0.559
Precuneus_AD_VOI 0.618 ± 0.098 0.438 to 0.776 0.016
PCG_AD_VOI 0.716 ± 0.092 0.538 to 0.855 0.078
Medial_Occipital_VOI 0.614 ± 0.102 0.435 to 0.773 0.032
Lateral_Occipital_VOI 0.585 ± 0.100 0.407 to 0.748 0.021
Whole_Occipital_VOI 0.631 ± 0.098 0.451 to 0.787 0.029
VOI volume of interest, SE standard error, CI confidence interval, PCG posterior
cingulate gyri, CISmedO PCG_AD_VOI/Medial_Occipital_VOI, CISlatO
PCG_AD_VOI/Lateral_Occipital_VOI, CISwO PCG_AD_VOI/Whole_Occipital_VOI
aThe AUCs of the ROC curves were compared to those thresholded with
CISpreC [23]. The italicized p values were not significantly different from the
AUC thresholded with CISpreC
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between 30 and 85 % [28]. Generally, high rates of posi-
tive amyloid scans are consistent with the high patho-
logical frequency of amyloid plaques; thus, it is unlikely
that amyloid PET would be helpful in differentiating
DLB from AD in our study.
In discriminating DLB from AD clinically, Shimizu et
al. [3] reported over 90 % sensitivity and specificity
using DAT imaging [1] and [123I]MIBG myocardial
scintigraphy [2]. With these images, early disturbances
of the nigrostriatum or peripheral sympathetic nervous
system in patients with DLB can be detected directly
more accurately comparing with our results. However,
brain perfusion single-photon emission computed tom-
ography (SPECT) is more widely and commonly used
for clinical screening and examination of patients with
dementia. SPECT reveals useful information for differ-
entiating AD as well as other dementias, including vas-
cular dementia or frontotemporal lobe degeneration
[5]. Compared with morphometric imaging, SPECT is a
more sensitive modality for functional imaging used to
detect the early stages of neurodegenerative disease be-
fore shrinkage in AD [4].
O’Brien et al. [12] claimed that brain perfusion SPECT
imaging did not reveal the CIS in patients with DLB. Al-
though, in this study, obtained AUC was almost equal to
O’Brien’s results, those obtained from ROI analysis with
[18F]FDG-PET. It is speculated that when our procedure
is applied to [18F]FDG-PET images, AD and DLB might
be more accurately differentiated. But brain perfusion
SPECT is not only more commonly used but is also a
more economical modality compared with [18F]FDG-
PET.
Conclusions
Using the CIS within the early-AD-specific VOI, DLB
and AD were differentiated with 80 % accuracy. This ac-
curacy was superior to the differentiation ability of the
medial occipital VOI analysis. Although differentiation
of DLB from AD is difficult with visual inspection [12],
our findings indicate that the Z-score ratio of the
posterior cingulate and the precuneus within the
early-AD-specific VOI is clinically useful in discriminat-
ing demented patients with DLB from those with AD.
Fig. 3 Box plots of CISpreC, CISmedO, CISlatO, CISwO, PCG_AD_VOI, and three occipital VOIs. a CISpreC. b CISmedO, c CISlatO, d CISwO, e
Average positive Z-scores in the PCG_AD_VOI, f Average positive Z-score in the Medial_Occipital_VOIs. g Average positive Z-score in the
Lateral_Occipital_VOIs. h Average positive Z-score in the Whole_Occipital_VOIs. The rhombus shows the mean and confidential interval. The boxes
show the upper and lower quantiles with the median, and the whiskers show the minimum, maximum, or 1.5 * interquartile range
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Additional file
Additional file 1: Tables S1–S2. Areas where proportionally significant
decrease perfusion was found in patients with DLB comparing to
patients with AD. (DOCX 14 kb)
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